The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EN | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
| Code | Title | |
|---|---|---|
| L01EN01 | Erdafitinib | |
| L01EN02 | Pemigatinib | |
| L01EN03 | ||
| L01EN04 |
| Active Ingredient | Description | |
|---|---|---|
| Erdafitinib |
Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Erdafitinib increases serum phosphate concentration, a secondary effect of FGFR inhibition. |
|
| Futibatinib |
Constitutive fibroblast growth factor receptor (FGFR) signalling can support the proliferation and survival of malignant cells. Futibatinib is a tyrosine kinase inhibitor that irreversibly inhibits FGFR 1, 2, 3, and 4 by covalent binding. |
|
| Pemigatinib |
Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3 which inhibits FGFR phosphorylation and signalling and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements. FGFR2 fusions/rearrangements are strong oncogenic drivers and are the most common FGFR alteration occurring, almost exclusively, in 10-16% of intrahepatic cholangiocarcinoma (CCA). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BALVERSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LYTGOBI Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PEMAZYRE Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PEMAZYRE Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
